Avaliação dos eventos adversos das vacinas aprovadas para fase 4 contra o vírus SARS-CoV-2.
Data
2022-07-27
Autores
Silva, Juliana Moura Narducci da 
Orientadores
Fonseca, Fernando Luiz Affonso
Tipo
Trabalho de conclusão de curso
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Devido a pandemia causada pela doença do coronavírus de 2019 (COVID-19), foi necessário o desenvolvimento de novas vacinas com o intuito de combater a pandemia, este trabalho teve como objetivo avaliar os eventos adversos das vacinas em fase 4 aprovadas pela Organização Mundial da Saúde em relação a quais são seus principais eventos adversos para cada população.
A avaliação foi realizada através de uma análise de artigos publicados, estes artigos foram localizados por uma busca realizada no PubMed, os termos chaves da busca estavam relacionados a vacina, COVID-19 e eventos adverso. Como resultado foram encontrados estudos relacionados as vacinas CoronaVac, BBIBP-CorV, Covishield/ Vaxzevria, Convidecea, COVID-19 Vaccine Janssen, Spikevax e Comirnaty, em diferentes quantidades.
Após a análise dos artigos, pode-se concluir que as vacinas se demostraram seguras para uso em humanos, apesar de ainda necessitarem de estudos a longo prazo. Devido a quantidade de estudos encontrados, não foi possível avaliar para todas as vacinas os eventos adversos de cada população. Foi observado uma maior incidência de eventos adversos em mulheres com menos de 50 anos de idade que receberam a vacina Covishield e a que a ocorrência de miocardite em adolescentes com idades entre 12 e 17 foi maior do que o esperado pelos dados dos estudos clínicos após o recebimento da vacina Comirnaty.
Due to the pandemic caused by the 2019 coronavirus disease (COVID-19), it was necessary to develop new vaccines in order to combat the pandemic, this work aimed to evaluate the adverse events of phase 4 vaccines approved by the World Organization of Health (WHO) in relation to what are its main adverse events for each population. The evaluation was performed through an analysis of published articles, these articles were located by a search performed on PubMed, the key search terms were related to vaccine, COVID-19 and adverse events. As a result, studies related to CoronaVac, BBIBP-CorV, Covishield / Vaxzevria, Convidecea, COVID-19 Vaccine Janssen, Spikevax and Comirnaty vaccines were found in different amounts. After analyzing the articles, it can be concluded that the vaccines proved to be safe for use in humans, although they still need long-term studies. Due to the number of studies found, it was not possible to evaluate the adverse events of each population for all vaccines. Higher incidence of adverse events was observed in women under 50 years of old who received the Covishield vaccine and to whom the occurrence of Myocarditis in adolescents between 12 and 17 years old was higher than expected from clinical trial data after receiving the Comirnaty vaccine.
Due to the pandemic caused by the 2019 coronavirus disease (COVID-19), it was necessary to develop new vaccines in order to combat the pandemic, this work aimed to evaluate the adverse events of phase 4 vaccines approved by the World Organization of Health (WHO) in relation to what are its main adverse events for each population. The evaluation was performed through an analysis of published articles, these articles were located by a search performed on PubMed, the key search terms were related to vaccine, COVID-19 and adverse events. As a result, studies related to CoronaVac, BBIBP-CorV, Covishield / Vaxzevria, Convidecea, COVID-19 Vaccine Janssen, Spikevax and Comirnaty vaccines were found in different amounts. After analyzing the articles, it can be concluded that the vaccines proved to be safe for use in humans, although they still need long-term studies. Due to the number of studies found, it was not possible to evaluate the adverse events of each population for all vaccines. Higher incidence of adverse events was observed in women under 50 years of old who received the Covishield vaccine and to whom the occurrence of Myocarditis in adolescents between 12 and 17 years old was higher than expected from clinical trial data after receiving the Comirnaty vaccine.